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Melanocortins are known to be involved in the regulation of feeding behavior. These hormones mediate their effects through G protein-
coupled receptors (GPCRs) by stimulating adenylate cyclase. The melanocortin 3 receptor (MC3R) in the melanocortin receptor (MCR)
family has been identified as a neural receptor subtype mainly expressed in the brain in mammals. Until now, only one heterozygous mutation
(I183N) has been identified in the coding region of this receptor in two obese patients of the same family. In this study, we reported the
functional characterization of the I183N mutated MC3R compared with that of the wild-type MC3R after transfection in HEK293 cells.
Our results showed that the I183N mutation totally abolished the activity of the mutated receptor to generate intracellular cAMP.
Furthermore, confocal microscopy observation revealed that the mutation induced an intracellular retention of the mutated receptor.
Moreover, we demonstrated for the first time by co-transfection studies that the mutated receptor could reduce the wild-type receptor activity
through a dominant negative effect.
D 2004 Elsevier B.V. All rights reserved.Keywords: Melanocortin-3 receptor; Obesity; Mutation; Dominant negative effect1. Introduction
Obesity is a complex multifactorial disease caused by the
interaction of multiple genetic, environmental and behavioral
factors. The central melanocortin system is involved in the
regulation of energy homeostasis in humans and rodents. The
melanocortin receptor (MCR) family consists of five iso-
forms (MC1R–MC5R) identified so far [1–6] and belongs
to the G protein coupled receptor (GPCR) superfamily.
The melanocortin peptides (a, h, and g melanocyte
stimulating hormones and ACTH) derived by posttransla-
tional processing of the proopiomelanocortin (POMC) are
the endogenous agonist ligands for these receptors. The
MCRs exhibit distinct physiological functions and tissue-
specific expression.
The respective inactivation of the mouse melanocortin 3
receptor (MC3R) and MC4R has demonstrated the critical0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2004.03.009
Abbreviations: NDP-MSH, (Nle4, D-Phe7) a melanocyte-stimulating
hormone; ACTH, adrenocorticotropic hormone; MCR, melanocortin
receptor; EGFP, enhanced green fluorescent protein; GPCR, G protein-
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contrast to MC4R knockout mice which exhibit increased
food intake, increased somatic growth and defects in meta-
bolism, MC3R knockout mice exhibit an exclusively meta-
bolic syndrome. The MC3R / mice have increased fat
mass, reduced lean mass caused by increased feed efficiency
but not hyperphagia associated with reduced energy expen-
diture. Mice lacking both MC3R and MC4R have exacer-
bated obesity compared to MC4R / mice consistent with
the non-redundant role of the two receptors in regulating
body weight [9]. However, heterozygous mice for MC3R or
MC4R exhibited an intermediate phenotype [7–9].
Several mutations in the MC4R leading to complete loss
of functions have been associated with rare extreme obesity
in humans [10,11]. Based on the structure/function similar-
ity of the MC3R and the MC4R [3] and since a locus
encoding MC3R on human chromosome 20q13 seems to
contribute to body fat and insulin level in a human popu-
lation[12–14], mutations in the MC3R gene may play a role
in the pathogenesis of obesity. Variations of the human
MC3R gene were investigated in a large cohort of extremely
obese and type 2 diabetes mellitus patients and only two
variants were found but none of them was associated with
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ciations between MC3R polymorphisms in non-coding
regions and obesity-related phenotypes have also been
reported [18,19].
Recently, a novel mutation (I183N) was found in hetero-
zygosity in a 13-year-old obese girl and her father [20] but
functional analysis of this MC3R mutation has not been
reported. Since we have developed an in vitro expression
model for the human MC3R tagged at its C terminus with
the enhanced green fluorescent protein (EGFP) [21], we
reported here the functional characterization of the human
I183N mutated MC3R expressed in HEK 293 cells.2. Materials and methods
2.1. Materials
Fetal calf serum (FCS), Dulbecco’s Modified Eagle
Medium/Ham’s nutrient mixture F12 (DMEM/F12 1:1),
LipofectAmine Plus reagent, and L-glutamine were pur-
chased from Invitrogen (Cergy Pontoise, France); 3-iso-
butyl-1-methyl-xanthine (IBMX) was from Sigma-Aldrich
(St Quentin Fallavier, France); (Nle4, D-Phe7)aMSH
(NDP-MSH) was from Bachem (Voisins le Bretonneux,
France).
2.2. Constructions of expression vectors
The full-length coding sequence of the wild-type hMC3R
was amplified by polymerase chain reaction (PCR) from
human genomic DNA using specific primers and sub-
cloned into the pEGFP-N2 expression vector as described
previously[21].
Mutated receptor was generated from the cloned wild-
type hMC3R by site-directed mutagenesis. Primers were
designed from the sequence in the second intracellular loop
domain of the MC3R using recommended protocol (Quik-
Change site-directed mutagenesis kit, Stratagene, The Neth-
erlands). Briefly, denatured double-stranded DNA vector
was annealed to a mutagenic primer pair of forward and
reverse oligonucleotides (sense 5V-CAGGTACGTC-
ACCAACTTTTACGCGCTCCG-3V, ant isense 5V-
CGGAGCGCGTAAAAGTTGGTGACGTACCTG-3V) and
the new strand of DNA containing the desired mutation was
synthesised with Pfu DNA polymerase (pfu Turbo DNA
polymerase, Stratagene) by PCR (conditions: 95 jC for 30
s; 94 jC for 30 s, 55 jC for 1 min, and 68 jC for 13 min
repeated 14 cycles; 68 jC for 10 min). Methylated template
DNA was digested with DpnI enzyme for 1 h at 37 jC.
Reaction mixtures were then used to transform Max DH5a
competent cells (Invitrogen). Inserts of plasmid DNA of
several colonies were totally sequenced confirming the
presence of the mutation (I183N), and that no errors were
induced by PCR. These plasmids were then used for
transfection.2.3. Transfection in HEK293 cells
The day before transfection, HEK293 cells (human
embryonic kidney) were plated on six-well dishes at 2.5
105 cells/well in DMEM/F12 medium supplemented with
FCS (7.5%) and 2 mM L-glutamine. Transfections were
performed with 1 Ag of plasmids in serum-free DMEM/F12
medium without antibiotics, using the LipofectAMINE
PLUS reagent according to the manufacturer’s protocol as
previously described [22].
2.4. Northern blot analysis
The expression of the wild-type and mutated MC3R-
EGFP was evaluated by Northern blot analysis after extrac-
tion of total RNA from the parental cell line and from
transiently transfected HEK293 cells as previously de-
scribed [23]. Hybridizations were performed using the entire
coding sequence of the EGFP or the hMC3R as a probe,
labeled in the presence of [a-32P]-deoxy-CTP using the
Rediprime DNA labeling system (Amersham Pharmacia
Biotech, Orsay, France). The relative intensity of hybridiza-
tion signals was quantified by image analysis and equal
loading of RNA samples was confirmed by scanning the
28S negatives (SAMBA 2005, Alcatel TITN, Meylan,
France).
2.5. cAMP measurement
To study the coupling of the wild-type MC3-R-EGFP,
or the I183N mutated MC3R-EGFP receptor, to adenylate
cyclase in the HEK293 cells transiently expressing each
one of them, NDP-MSH dose-responses were performed.
Forty-eight hours after transfection, cells were stimulated
for 20 min with increasing concentrations of NDP-MSH
in the presence of 1 mM IBMX to inhibit phosphodies-
terases, then recovered and the intracellular accumulation
of cAMP was measured by radioimmunological assay
using 125I-labeled cAMP (Beckman Coulter, Roissy,
France) [24].
2.6. Fluorescence microscopy
Cells were plated on 10-cm-diameter dishes at 2.106
cells/dish. Transient transfections were made using the
LipofectAMINE PLUS reagent as described above. Twen-
ty-four hours after transfection, cells were observed on
fluorescence confocal microscopy (Leica Microsystems
SA, Rueil Malmaison, France) after stimulation with UV
(488 nm).
2.7. Co-transfection studies
HEK293 cells were transiently transfected as described,
with 0.1 Ag of wild-type MC3R-EGFP construct in the
absence or presence of different amounts of I183N mutated
ysica Acta 1689 (2004) 229–234
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total amount of DNA transfected each time was identical (1
Ag/well). Cells were stimulated 48 h after transfection with
0.5 nM of NDP-MSH. Intracellular cAMP production was
then measured as described above.Fig. 2. cAMP accumulation assays. Intracellular cAMP production in
HEK293 cells transiently expressing wild-type or I183N mutated MC3R
fused to EGFP in response to increasing concentrations of NDP-MSH. Each
point represents the meanF S.E. of three independent experiments
performed in triplicate. Basal cAMP production in absence of agonist
stimulation was 4.6F 0.52 pmol/106 cells (n= 3).3. Results
We have generated the I183N mutation in the human
MC3R by site-directed mutagenesis from the cloned wild-
type MC3R fused to EGFP on its carboxy-terminal tail
previously described [21]. The wild-type MC3R and the
I183N mutated receptor were transiently expressed in
HEK293 cells for further functional analysis.
Northern blot analysis revealed similar levels of mRNA
encoding wild-type or I183N mutated MC3R fused to EGFP
in transiently transfected HEK293 cells, using an MC3R
probe or an EGFP probe (Fig. 1). As expected, parental
HEK293 cells exhibited no specific hybridization signal,
which confirmed the absence of endogenous MC3R in this
cell line.
Functional analysis of the transiently transfected HEK293
cells was realized by measuring the intracellular cAMP
levels after stimulation by increasing concentrations of the
agonist NDP-MSH [25]. Whereas the cells transfected with
the wild-type MC3R-EGFP plasmid produced cAMP in aFig. 1. Northern blot analysis. Bottom: Representative Northern blot
analysis of 15-Ag total RNA extracted from parental HEK293 cells (1),
transiently transfected HEK293 cells with wild-type MC3R (2) or I183N
mutated MC3R (3) fused to EGFP after hybridizations with the MC3R or
the EGFP probes. Top: Relative intensity of hybridization signals over
28S RNA.
Fig. 3. Confocal microscopy observation. Fluorescent confocal microscope
images of HEK293 cells transiently expressingwild-typeMC3R (a) or I183N
mutated MC3R (b) fused to EGFP, after stimulation with UV (488 nm).
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(n = 5), the cells transfected with the I183N mutated MC3R-
EGFP plasmid did not exhibit cAMP production at any
NDP-MSH concentration used (Fig. 2). These results sug-
gest a defect in the coupling of the mutated I183N receptor
to intracellular effectors. We next investigated the subcel-
lular localization of this mutated receptor since the hMC3R-
EGFP fusion protein can be easily visualized by confocal
microscopy observation after stimulation with UV as pre-
viously reported [21]. As shown in Fig. 3a, in cells trans-
fected with the wild-type MC3R-EGFP, the fluorescent
signal was detected at the plasma membrane as well as in
perinuclear position, confirming that the fusion protein was
well expressed and addressed to the cell membrane. In
contrast, in cells transfected with the I183N mutated MC3R
coupled to EGFP (Fig. 3b), there was no cell surface
fluorescence but a strong intracellular signal was observed,
indicating that the mutated receptor accumulated intracel-
lularly. Since the I183N mutation was found in heterozy-
gous form and co-segregate with an obese phenotype, one
hypothesis could be that the mutated receptors might exert
its action through dominant-negative effects on coexpressed
wild-type receptors.
To test this hypothesis, HEK293 cells were co-trans-
fected at different ratios of the wild-type MC3R to I183N
mutated receptors while maintaining a constant total DNA
amount. As observed in Fig. 4, after 48 h, intracellular
cAMP production in co-transfected HEK293 cells in re-
sponse to 0.5 nM NDP-MSH decreased depending upon the
amount of I183N mutated MC3R transfected. Since the
amount of wild-type MC3R transfected was always con-
stant, these results suggest a dominant-negative effect of the
mutated receptor.Fig. 4. Co-transfection studies. cAMP production in response to 0.5 nM
NDP-MSH in HEK293 cells co-transfected at a ratio of 1:1, 1:2 or 1:9 of
wild-type MC3R (WT) to I183N mutated MC3R (I183N). Data are
expressed as a percentage of production of cAMP in co-transfected cells
compared to cells transfected with wild-type MC3R alone. Each point
represents the meanF S.D. of one experiment performed in triplicate. The
experiment was repeated three times with similar results.4. Discussion
Different research groups reported a strong evidence
for linkage between obesity phenotypes and loci in human
chromosome 20q which encodes MC3R [12–14]. In the
same cohort as those of Lembertas et al. [12], an insertion
polymorphism in the 3V region of MC3R was shown to
be associated with the level of fat in non-obese subjects
[18]. Several groups have investigated to determine the
variations of the human MC3R gene in large cohort of
extremely obese and type 2 diabetes individuals [15–
17,19]. To date, only two variants in coding region (I81V
and K6T) have been described and were not associated
with diabetes or obesity. The I183N mutation was the first
human MC3R mutation found in heterozygosity in a 13-
year-old obese girl and her father [20]. Since this muta-
tion was not found in 121 control individuals without
obesity, it is likely that the mutated MC3R exhibits some
abnormal functions.
The I183N mutation is located in the second intracellular
loop of the MC3R, which is implicated in the interaction
with G-protein to mediate signal transduction in other
GPCR [26]. Moreover, this isoleucine is a conserved residue
among all the other MCRs [27]. Therefore, it is likely that
mutation of isoleucine with a nonpolar side chain to
asparagine with a polar side chain could modify the function
of the MC3R. To date, no mutation at the corresponding
position has been described for the other MCRs, whereas
several mutations have been identified in the second intra-
cellular loop of the human MC2R and the human MC4R in
familial glucocorticoid deficiency patients [22] and extreme-
ly obese patients [10,11,28,29], respectively. However,
functional analysis was necessary to confirm that I183N
mutation could be responsible for the metabolic syndrome
observed in the carrier patients.
By transient transfection studies with the I183N mutated
MC3R coupled to EGFP, we demonstrated that the mutation
I183N completely abolished the activation of the mutated
MC3R by the agonist NDP-MSH whereas the NDP-MSH
response of the wild-type MC3R in the same experimental
conditions was similar to those described previously [21].
As demonstrated by Northern blot analysis and confocal
microscopy studies, these different responses to ligand were
not related to different levels of transfection or expression of
the fusion protein between the wild-type MC3R and the
I183N mutated MC3R. In fact, the I183N mutated MC3R
was intracellularly retained without expression at the cell
surface, leading to the absence of agonist response. This
defect seems to be a common feature of mutant MCRs.
Indeed, previous studies have reported that MC4R muta-
tions associated with obesity caused also partial or comple-
ted intracellular retention of mutant receptors [29–33].
The I183N mutation of the MC3R was found in hetero-
zygosity in the proband and her father, although the per-
centage of his body fat was less elevated than for the
proband [20]. So, the obese phenotype in this family could
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dominant negative mechanism of the mutated MC3R over
the wild-type receptor function. Such hypothesis has already
been suggested for MC4R. In fact, this was strongly
supported by a study which failed to detect obesity due to
haploinsufficiensy of the MC4R gene in several individuals
with deletion of 18q including the MC4R gene [34].
Moreover, Vaisse et al. [10] have reported that obesity-
associated defects in MC4R range from loss of function to
constitutive activation, indicating a variable expressivity of
these mutations. In the same way, heterozygous MC3R /+
and MC4R /+ transgenic mice also display a variability in
phenotype from intermediate phenotype to wild type or
homozygous phenotype. Until recently, the hypothesis that
obesity in the heterozygous carriers of the MC4R mutations
resulted from haploinsufficiency was the most common
[11,28,30,32]. In fact, there was no evidence that obesity-
associated heterozygous MC4R mutations could exert dom-
inant negative effect on the wild-type MC4R [30,32].
However, such dominant negative effects have been
reported for several mutant receptors which are able to form
homo- or heterodimers [35,36].
In conclusion, our in vitro expression studies have clearly
demonstrated a loss of function of the I183N mutated
MC3R, arguing that the MC3R mutation maybe the cause
of the abnormal development of the fat mass in the carrier
patients. These results confirm that in humans, as in mice,
MC3R is mostly involved in energy storage and fat metab-
olism. Moreover, for the first time we have demonstrated
that the mutated receptor reduced the activity of the wild-
type receptor in a co-transfection assay, suggesting that
probably these MCRs are able to oligomerize. These results
are in favour of a dominant negative mechanism of the
mutated receptor on the wild-type receptor in heterozygous
carrier patients rather than haploinsufficiency which could
result in variable phenotypes.Acknowledgements
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